NEFL and myeloid sarcoma: The primary CSF biomarkers which can be used to predict the prognosis of MS are β-amyloid (Aβ) levels, neurofilament light (NF-L), neurofilament heavy (NF-H), chitinase 3-like-1 (CHI3L1) and immunoglobulin M (IgM) [33,34].